cosibelimab
fortress,tg therapeutics,Checkpoint Therapeutics 
['cosibelimab', 'pivotal']
checkpoint therapeutics announced the presentation of data from its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cscc) during #asco22. positive top-line results were previously announced in jan 2022. more info: $ckpt $fbio
Fortress Biotech is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. $FBIO